Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist

Life Sciences

Volumn 91, Issue 13-14, 2012, Pages 658-668

  Sen, S ^a   Chen, S ^a   Feng, B ^a   Iglarz, M ^b   Chakrabarti, S ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Diabetic complications; Endothelin; Macitentan; Type 2 diabetes

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 4; CREATININE; ENDOTHELIN 1; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACITENTAN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART DISEASE; HEART HEMODYNAMICS; HYPERGLYCEMIA; KIDNEY HYPERTROPHY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; URINALYSIS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; KIDNEY; MALE; MICE; MYOCARDIUM; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RETINA; SULFONAMIDES; TIME FACTORS;

ANIMALIA; MUS;

EID: 84867572568     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.03.032     Document Type: Conference Paper

References (70)

1. S. Adiarto, N. Emoto, N. Iwasa, and M. Yokoyama Obesity-induced upregulation of myocardial endothelin-1 expression is mediated by leptin Biochem Biophys Res Commun 353 2007 623 627
2. E.D. Bartels, J.M. Nielsen, L.S. Bisgaard, J.P. Goetze, and L.B. Nielsen Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice Endocrinology 151 2010 5218 5225
3. M. Barton Reversal of proteinuric renal disease and the emerging role of endothelin Nat Clin Pract Nephrol 4 2008 490 501
4. D.S. Bell Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease Diabetes Care 18 1995 708 714
5. L. Benatti, M.S. Fabbrini, and C. Patrono Regulation of endothelin-1 biosynthesis Ann N Y Acad Sci 18 714 1994 109 121
6. A. Benigni, V. Colosio, C. Brena, I. Bruzzi, T. Bertani, and G. Remuzzi Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes Diabetes 47 1998 450 456
7. J.A. Breyer, R.P. Bain, J.K. Evans, N.S. Nahman Jr., E.J. Lewis, and M. Cooper Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group Kidney Int 50 1996 1651 1658
8. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
9. J. Cai, and M. Boulton The pathogenesis of diabetic retinopathy: old concepts and new questions Eye (Lond) 16 2002 242 260
10. C. Chatziantoniou, and J.C. Dussaule Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 289 2005 F227 F234
11. S. Chen, M. Apostolova, G. Cherian, and S. Charkrabarti Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells Lab Invest 80 2000 1311 1321
12. S. Chen, T. Evans, D. Deng, M. Cukiernik, and S. Chakrabarti Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins Nephron 90 2002 86 94
13. S. Chen, Z.A. Khan, M. Cukiernik, and S. Chakrabarti Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications Am J Physiol Endocrinol Metab 284 2003 E1089 E1097
14. S. Chen, S. Mukherjee, C. Chakraborty, and S. Chakrabarti High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1 Am J Physiol Cell Physiol 284 2003 C263 C272
15. J. Chiu, B.Y. Xu, S. Chen, B. Feng, and S. Chakrabarti Oxidative stress-induced, poly (ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications Can J Physiol Pharmacol 86 2008 365 372
16. D. Deng, T. Evans, K. Mukherjee, D. Downey, and S. Chakrabarti Diabetes-induced vascular dysfunction in the retina: role of endothelins Diabetologia 42 1999 1228 1234
17. G. Dogra, L. Rich, K. Stanton, and G.F. Watts Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria Diabetologia 44 2001 593 601
18. J.C. Dussaule, and C. Chatziantoniou Reversal of renal disease: is it enough to inhibit the action of angiotensin II? Cell Death Differ 14 2007 1343 1349
19. T. Emori, Y. Hirata, T. Imai, K. Ohta, K. Kanno, and S. Eguchi Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell Biochem Pharmacol 44 1992 2409 2411
20. T. Evans, D.X. Deng, S. Chen, and S. Chakrabarti Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats Diabetes 49 2000 662 666
21. H. Farhangkhoee, Z.A. Khan, S. Chen, and S. Chakrabarti Differential effects of curcumin on vasoactive factors in the diabetic rat heart Nutr Metab (Lond) 3 2006 27
22. I.S. Farooqi Monogenic human obesity Front Horm Res 36 2008 1 11
23. I.S. Farooqi, and S. O'Rahilly Recent advances in the genetics of severe childhood obesity Arch Dis Child 83 1 2000 31 34
24. I.S. Farooqi, and S. O'Rahilly Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity Nat Clin Pract Endocrinol Metab 4 2008 569 577
25. Q. Feng, X. Lu, D.L. Jones, J. Shen, and J.M. Arnold Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice Circulation 104 2001 700 704
26. E. Gagliardini, D. Corna, C. Zoja, F. Sangalli, F. Carrara, and M. Rossi Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes Am J Physiol Renal Physiol 297 2009 F1448 F1456
27. E. Gagliardini, S. Buelli, and A. Benigni Endothelin in chronic proteinuric kidney disease Contrib Nephrol 172 2011 171 184
28. M.L. Gross, A. El-Shakmak, A. Szábó, A. Koch, A. Kuhlmann, and K. Münter ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy Diabetologia 46 2003 856 868
29. M.L. Gross, E. Ritz, A. Schoof, B. Helmke, A. Parkman, and O. Tulp Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker Lab Invest 83 2003 1267 1277
30. M.L. Gross, N. Heiss, M. Weckbach, A. Hansen, A. El-Shakmak, and A. Szabo ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes Diabetologia 47 2004 316 324
31. M. Houde, J. Labonté, and P. D'Orléans-Juste Peptide and non-peptide antagonists targeting endothelin receptors in physiology and pathology Curr Pharm Des 17 2011 2613 2625
32. M. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield, and A. Treiber Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist J Pharmacol Exp Ther 327 2008 736 745
33. M.T. Johnstone, S.J. Creager, K.M. Scales, J.A. Cusco, B.K. Lee, and M.A. Creager Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus Circulation 88 1993 2510 2516
34. S. Kanda, R. Nakashima, K. Takahashi, J. Tanaka, J. Ogawa, and T. Ogata Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models J Pharmacol Sci 111 2009 155 166
35. Z.A. Khan, and S. Chakrabarti Endothelins in chronic diabetic complications Can J Physiol Pharmacol 81 2003 622 634
36. Z.A. Khan, M. Cukiernik, J.R. Gonder, and S. Chakrabarti Oncofetal fibronectin in diabetic retinopathy Invest Ophthalmol Vis Sci 45 2004 287 295
37. M. Kohno, T. Horio, K. Yokokawa, N. Kurihara, and T. Takeda C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3′,5′-monophosphate Hypertension 19 1992 320 325
38. R.A. Kowluru, and M. Kanwar Effects of curcumin on retinal oxidative stress and inflammation in diabetes Nutr Metab (Lond) 4 2007 8
39. O. Kummer, M. Haschke, F. Hammann, M. Bodmer, S. Bruderer, and Y. Regnault Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan Eur J Pharm Sci 38 2009 384 388
40. H. Kurihara, M. Yoshizumi, T. Sugiyama, F. Takaku, M. Yanagisawa, and T. Masaki Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells Biochem Biophys Res Commun 159 1989 1435 1440
41. J. Lambert, M. Aarsen, A.J. Donker, and C.D. Stehouwer Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus Arterioscler Thromb Vasc Biol 16 1996 705 711
42. E.R. Levin Endothelins N Engl J Med 333 1995 356 363
43. J. Li, J.J. Wang, Q. Yu, K. Chen, K. Mahadev, and S.X. Zhang Inhibition of reactive oxygen species by lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4 Diabetes 59 2010 1528 1538
44. M. Magnusson, O. Maleander, B. Israelsson, A. Grubb, L. Groop, and S. Jovinge Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease Diabetes Care 27 2004 1929 1935
45. M.A. Malek Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology Pharmacol Rev 46 1994 325 415
46. A.M. Malek, J. Zhang, J. Jiang, S.L. Alper, and S. Izumo Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels J Mol Cell Cardiol 31 1999 387 399
47. R. Mishra, S.N. Emancipator, T.S. Kern, and M.S. Simonson Association between endothelin-1 and collagen deposition in db/db diabetic mouse kidneys Biochem Biophys Res Commun 339 2006 65 70
48. A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, and K. Baumann Endothelin stimulates vascular hydroxyl radical formation: effect of obesity Am J Physiol Regul Integr Comp Physiol 293 2007 R2218 R2224
49. T. Nakamura, I. Ebihara, M. Fukui, Y. Tomino, and H. Koide Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli Diabetes 44 1995 895 899
50. M.G. Nannipieri, G.C. Seghieri, C.T. Catalano, T.S. Prontera, and B.E. Ferrannini Defective regulation and action of atrial natriuretic peptide in type 2 diabetes Horm Metab Res 34 5 2002 265 270
51. E.B. Okon, T. Szado, I. Laher, B. McManus, and C. van Breemen Augmented contractile response of vascular smooth muscle in a diabetic mouse model J Vasc Res 40 2003 520 530
52. T. Peng, X. Lu, M. Lei, G.W. Moe, and Q. Feng Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia Cardiovasc Res 59 2003 893 900
53. T.J. Rabelink, and D.E. Kohan Endothelin receptor blockade in patients with diabetic nephropathy Contrib Nephrol 172 2011 235 242
54. T. Radovits, S. Korkmaz, S. Loganathan, E. Barnucz, T. Bömicke, and R. Arif Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus Am J Physiol Heart Circ Physiol 297 2009 H125 H133
55. S.G. Raja Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis Curr Opin Investig Drugs 11 2010 1066 1073
56. G. Remuzzi, A. Benigni, and A. Remuzzi Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes J Clin Invest 116 2006 288 296
57. G.M. Rubanyi, and M.A. Polokoff Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology Pharmacol Rev 46 1994 325 415
58. M.A. Saleh, E.I. Boesen, J.S. Pollock, V.J. Savin, and D.M. Pollock Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model Diabetologia 54 2011 979 988
59. M.A. Saleh, J.S. Pollock, and D.M. Pollock Distinct actions of endothelin a-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease J Pharmacol Exp Ther 8 2011 263 270
60. P.N. Sidharta, P.L. van Giersbergen, A. Halabi, and J. Dingemanse Macitentan: entry-into-humans study with a new endothelin receptor antagonist Eur J Clin Pharmacol 67 2011 977 984
61. M.S. Simonson, M. Tiktun, S.M. Debanne, M. Rahman, B. Berger, and D. Hricik The renal transcriptome of db/db mice identifies putative urinary biomarkers proteins in patients with type 2 diabetes: a pilot study Am J Physiol Renal Physiol 302 2011 F820 9
62. N.C. Turner, P.J. Morgan, A.C. Haynes, M. Vidgeon-Hart, N. Toseland, and J.C. Clapham Elevated renal endothelin-I clearance and mRNA levels associated with albuminuria and nephropathy in non-insulin-dependent diabetes mellitus: studies in obese fa/fa Zucker rats Clin Sci (Lond) 93 1997 565 571
63. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
64. L. Virag, and C. Szabo The therapeutic potential of poly (ADP-ribose) polymerase inhibitors Pharmacol Rev 54 2002 375 429
65. L.H. Wang, J.S. Liu, W.B. Ning, Q.J. Yuan, F.F. Zhang, and Z.Z. Peng Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice Pharmacology 88 2011 88 99
66. X. Xin, Z.A. Khan, S. Chen, and S. Chakrabarti Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis Lab Invest 84 2004 1451 1459
67. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, and Y. Mitsui A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 6163 1988 411 415
68. Y. Yano, A. Katsuki, E.C. Gabazza, K. Ito, M. Fujii, and M. Furuta Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria J Clin Endocrinol Metab 84 1999 2353 2356
69. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 6865 2001 782 787
70. A. Zoja, S. Cattaneo, F. Fiordailso, V. Lionetti, V. Zambell, and M. Sailo Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes Am J Physiol Renal Physiol 30 2011 F1114 23